Product Description

Indications: Napro-A Plus is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and is also used to reduce the risk of gastric ulcers in patients who require NSAID therapy and are at risk of developing NSAID-induced ulcers.

Pharmacology: This formulation combines an immediate-release esomeprazole layer with an enteric-coated naproxen core. Esomeprazole, a proton pump inhibitor, is released first in the stomach to reduce gastric acid secretion by inhibiting the H+/K+-ATPase enzyme in parietal cells. Naproxen, a non-steroidal anti-inflammatory drug (NSAID), is then released in the intestine, where it inhibits prostaglandin synthesis, providing anti-inflammatory, analgesic, and antipyretic effects. This dual mechanism helps reduce gastrointestinal side effects associated with NSAIDs.

Dosage & Administration: The dose should be individualized based on patient response and risk factors, using the lowest effective dose for the shortest duration. For adults with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, the recommended dose is one tablet twice daily (375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole). In adolescents (≥12 years) with juvenile idiopathic arthritis, dosing depends on body weight, with similar twice-daily regimens.

Administration: The tablet should be taken at least 30 minutes before meals. It must be swallowed whole and should not be split, chewed, crushed, or dissolved.

Interaction: Concomitant use with NSAIDs may reduce the effect of antihypertensive drugs such as ACE inhibitors, diuretics, and beta-blockers. Use with warfarin increases bleeding risk. Esomeprazole may affect the absorption of drugs dependent on gastric pH, such as ketoconazole, iron salts, and digoxin. High-fat meals may delay naproxen absorption and reduce peak plasma levels.

Contraindications: Contraindicated in patients with hypersensitivity to any component or substituted benzimidazoles, in those with a history of NSAID-induced asthma, urticaria or allergic reactions, and during the peri-operative period of coronary artery bypass graft (CABG) surgery.

Side Effects: Common adverse effects are gastrointestinal, including nausea, vomiting, abdominal pain, dyspepsia, constipation, diarrhea, and flatulence. Serious risks include gastric ulcers, bleeding, or perforation, especially in elderly patients. NSAIDs may also increase the risk of cardiovascular events such as myocardial infarction or stroke, and may cause edema, hypertension, or heart failure.

Pregnancy & Lactation: Use during the first and second trimester of pregnancy only if clearly necessary, and it is contraindicated during the third trimester. Naproxen is excreted in small amounts in breast milk, and esomeprazole excretion is unknown; therefore, use during breastfeeding is not recommended. NSAIDs may also impair female fertility and are not advised in women attempting to conceive.

Precautions & Warnings: Avoid concurrent use with other NSAIDs due to increased risk of adverse effects. Use cautiously in elderly patients, those with cardiovascular disease, gastrointestinal disorders, or renal impairment. Monitor for signs of GI bleeding, especially in high-risk patients. Long-term use may increase the risk of infections and reduce vitamin B12 absorption. Patients with hepatic or renal impairment require careful monitoring and possible dose adjustment.

Use in Special Populations: Elderly patients should receive the lowest effective dose due to increased risk of adverse effects. Not recommended in patients with severe renal impairment (creatinine clearance <30 ml/min). In mild to moderate hepatic impairment, use with caution; not recommended in severe hepatic impairment.

Overdose Effects: Naproxen overdose may cause lethargy, dizziness, abdominal pain, nausea, vomiting, GI bleeding, renal dysfunction, or metabolic acidosis. Severe cases may lead to respiratory depression or coma. Esomeprazole overdose is generally mild with no serious effects reported. Management is supportive, including activated charcoal if appropriate; there is no specific antidote.

Therapeutic Class: NSAIDs with proton pump inhibitor combination

Storage Conditions: Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.